Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyLisdexamfetamine
Identification
- Name
- Lisdexamfetamine
- Accession Number
- DB01255
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
Lisdexamfetamine (L-lysine-d-amphetamine) is a prodrug of the psychostimulant d-amphetamine coupled with the essential amino acid L-lysine. It was developed so that the amphetamine psychostimulant is released and activated more slowly as the prodrug molecule is hydrolyzed consequently cleaving off the amino acid-during the first pass through the intestines and/or the liver. Amphetamines target the trace amine-associated receptor 1 (TAAR1). Amphetamine is also believed to exert its effects by binding to the monoamine transporters (the dopamine transporter or DAT) and increasing extracellular levels of the biogenic amines dopamine, norepinephrine (noradrenaline) and serotonin.
- Structure
Structure for DB01255 (Lisdexamfetamine)
- Synonyms
- Lisdexamfetamine
- lisdexamfetamine dimesylate
- NRP104
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Vyvanse Capsule 20 mg/1 Oral Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc 2007-12-10 2018-03-22 US 
Vyvanse Capsule 70 mg/1 Oral Shire 2007-02-23 Not applicable US Vyvanse Capsule 70 mg Oral Shire Pharma Canada Ulc 2017-01-05 Not applicable Canada 
Vyvanse Capsule 20 mg/1 Oral Shire 2007-12-10 Not applicable US Vyvanse Capsule 50 mg Oral Shire Pharma Canada Ulc 2009-08-04 Not applicable Canada Vyvanse Capsule 70 mg/1 Oral Avera Mc Kennan Hospital 2015-09-30 2018-05-31 US Vyvanse Tablet, chewable 50 mg/1 Oral Shire 2017-01-28 Not applicable US Vyvanse Capsule 50 mg/1 Oral Physicians Total Care, Inc. 2008-07-11 Not applicable US Vyvanse Tablet, chewable 20 mg/1 Oral Shire 2017-01-28 Not applicable US Vyvanse Capsule 40 mg/1 Oral Shire 2007-12-10 Not applicable US - Categories
- Amines
- Amphetamine
- Amphetamines
- Central Nervous System Agents
- Central Nervous System Stimulants
- Centrally Acting Sympathomimetics
- Dextroamphetamine
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Ethylamines
- Membrane Transport Modulators
- Nervous System
- Neurotransmitter Agents
- Neurotransmitter Uptake Inhibitors
- Phenethylamines
- Psychoanaleptics
- Psychostimulants, Agents Used for Adhd and Nootropics
- Sympathomimetics
- UNII
- H645GUL8KJ
- CAS number
- 608137-32-2
- Weight
- Average: 263.3785
Monoisotopic: 263.199762437 - Chemical Formula
- C15H25N3O
- InChI Key
- VOBHXZCDAVEXEY-JSGCOSHPSA-N
- InChI
- InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1
- IUPAC Name
- (2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide
- SMILES
- C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN
Pharmacology
- Indication
For the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in pediatric populations aged 6 to 12 years.
- Associated Conditions
- Pharmacodynamics
Lisdexamfetamine is a pro-drug of dextroamphetamine. It works primarily by inducing the release of the neurotransmitters dopamine and norepinephrine from their storage areas in nerve terminals. Both of these transmitters contribute to maintaining alertness, increasing focus, and sustaining thought, effort, and motivation.
- Mechanism of action
Lisdexamfetamine is a pro-drug of dextroamphetamine. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Norepinephrine and dopamine contribute to maintaining alertness, increasing focus, and sustaining thought, effort, and motivation. However, the exact therapeutic action in ADHD is not known.
Target Actions Organism ASodium-dependent dopamine transporter inhibitorHuman UAlpha-1B adrenergic receptor antagonistHuman - Absorption
After oral administration, lisdexamfetamine is rapidly absorbed from the gastrointestinal tract.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Lisdexamfetamine is converted to dextroamphetamine and L-lysine, which is believed to occur by first-pass intestinal and/or hepatic metabolism. Lisdexamfetamine is not metabolized by cytochrome P450 enzymes.
- Route of elimination
- Not Available
- Half life
The plasma elimination half-life of lisdexamfetamine typically averaged less than one hour.
- Clearance
- Not Available
- Toxicity
Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia and rhabdomyolysis. Fatigue and depression usually follow the central nervous system stimulation. Cardiovascular effects include arrhythmias, hypertension or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 4-Methoxyamphetamine Lisdexamfetamine may decrease the vasoconstricting activities of 4-Methoxyamphetamine. Experimental, Illicit 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Lisdexamfetamine. Experimental Acebutolol Acebutolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved, Investigational Acepromazine Acepromazine may increase the antihypertensive activities of Lisdexamfetamine. Approved, Vet Approved Aceprometazine Aceprometazine may decrease the stimulatory activities of Lisdexamfetamine. Approved Acetazolamide Acetazolamide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Approved, Vet Approved Acetophenazine Acetophenazine may decrease the stimulatory activities of Lisdexamfetamine. Approved Acrivastine Lisdexamfetamine may decrease the sedative activities of Acrivastine. Approved Adrafinil Lisdexamfetamine may decrease the vasoconstricting activities of Adrafinil. Withdrawn Agmatine Lisdexamfetamine may decrease the vasoconstricting activities of Agmatine. Experimental, Investigational Alcaftadine Lisdexamfetamine may decrease the sedative activities of Alcaftadine. Approved Alfentanil Lisdexamfetamine may increase the analgesic activities of Alfentanil. Approved, Illicit Alfuzosin Alfuzosin may increase the antihypertensive activities of Lisdexamfetamine. Approved, Investigational Alimemazine Lisdexamfetamine may decrease the sedative activities of Alimemazine. Approved, Vet Approved Almasilate Almasilate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Approved, Experimental Aloglutamol Aloglutamol may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Approved Alphacetylmethadol Lisdexamfetamine may increase the analgesic activities of Alphacetylmethadol. Experimental, Illicit Alphaprodine Lisdexamfetamine may increase the analgesic activities of Alphaprodine. Illicit Alprenolol Alprenolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved, Withdrawn Aluminium Aluminium may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Approved, Investigational Aluminium acetoacetate Aluminium acetoacetate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Experimental Aluminium glycinate Aluminium glycinate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Experimental Aluminum hydroxide Aluminum hydroxide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Approved, Investigational Amibegron Lisdexamfetamine may decrease the vasoconstricting activities of Amibegron. Investigational Amineptine Amineptine may increase the stimulatory activities of Lisdexamfetamine. Illicit, Withdrawn Amiodarone Amiodarone may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved, Investigational Amisulpride Amisulpride may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational Amitraz Lisdexamfetamine may decrease the vasoconstricting activities of Amitraz. Vet Approved Amitriptyline Amitriptyline may increase the antihypertensive activities of Lisdexamfetamine. Approved Amitriptylinoxide Amitriptylinoxide may increase the stimulatory activities of Lisdexamfetamine. Approved, Investigational Amlodipine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Amlodipine. Approved Ammonium chloride The serum concentration of Lisdexamfetamine can be decreased when it is combined with Ammonium chloride. Approved, Investigational, Vet Approved Amoxapine Amoxapine may increase the antihypertensive activities of Lisdexamfetamine. Approved Amperozide Amperozide may decrease the stimulatory activities of Lisdexamfetamine. Experimental Amphetamine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Amphetamine. Approved, Illicit, Investigational Amrinone The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Amrinone. Approved Anisodamine Lisdexamfetamine may decrease the vasoconstricting activities of Anisodamine. Investigational Antazoline Lisdexamfetamine may decrease the sedative activities of Antazoline. Approved Apomorphine Lisdexamfetamine may decrease the vasoconstricting activities of Apomorphine. Approved, Investigational Apraclonidine Lisdexamfetamine may decrease the vasoconstricting activities of Apraclonidine. Approved Aranidipine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Aranidipine. Approved, Investigational Arbutamine Lisdexamfetamine may decrease the vasoconstricting activities of Arbutamine. Approved Arformoterol Lisdexamfetamine may decrease the vasoconstricting activities of Arformoterol. Approved, Investigational Aripiprazole Aripiprazole may increase the antihypertensive activities of Lisdexamfetamine. Approved, Investigational Arotinolol Arotinolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Investigational Ascorbic acid The serum concentration of Lisdexamfetamine can be decreased when it is combined with Vitamin C. Approved, Nutraceutical Asenapine Asenapine may increase the antihypertensive activities of Lisdexamfetamine. Approved Astemizole Lisdexamfetamine may decrease the sedative activities of Astemizole. Approved, Withdrawn Atenolol Atenolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved Avanafil Avanafil may increase the hypotensive activities of Lisdexamfetamine. Approved Azaperone Azaperone may decrease the stimulatory activities of Lisdexamfetamine. Investigational, Vet Approved Azatadine Lisdexamfetamine may decrease the sedative activities of Azatadine. Approved Azelastine Lisdexamfetamine may decrease the sedative activities of Azelastine. Approved Azelnidipine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Azelnidipine. Approved, Investigational Azimilide The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Azimilide. Investigational Bambuterol Lisdexamfetamine may decrease the vasoconstricting activities of Bambuterol. Approved, Investigational Bamipine Lisdexamfetamine may decrease the sedative activities of Bamipine. Experimental Barnidipine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Barnidipine. Approved Befunolol Befunolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Experimental Bencyclane The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Bencyclane. Experimental Benidipine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Benidipine. Approved, Investigational Benmoxin The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Benmoxin. Withdrawn Benperidol Benperidol may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational Benzatropine Lisdexamfetamine may decrease the sedative activities of Benzatropine. Approved Benzphetamine Lisdexamfetamine may decrease the vasoconstricting activities of Benzphetamine. Approved, Illicit Benzquinamide Lisdexamfetamine may decrease the sedative activities of Benzquinamide. Withdrawn Bepotastine Lisdexamfetamine may decrease the sedative activities of Bepotastine. Approved Bepridil The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Bepridil. Approved, Withdrawn Betahistine Lisdexamfetamine may decrease the sedative activities of Betahistine. Approved, Investigational Betaxolol Betaxolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved, Investigational Bevantolol Bevantolol may increase the antihypertensive activities of Lisdexamfetamine. Approved Bezitramide Lisdexamfetamine may increase the analgesic activities of Bezitramide. Experimental, Illicit, Withdrawn Bifeprunox Bifeprunox may decrease the stimulatory activities of Lisdexamfetamine. Investigational Bilastine Lisdexamfetamine may decrease the sedative activities of Bilastine. Approved, Investigational Bioallethrin The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Bioallethrin. Approved, Experimental Bismuth subcitrate potassium Bismuth Subcitrate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Approved, Investigational Bismuth subnitrate Bismuth subnitrate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Approved Bisoprolol Bisoprolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved Bitolterol Lisdexamfetamine may decrease the vasoconstricting activities of Bitolterol. Withdrawn Bopindolol Bopindolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved Brexpiprazole Lisdexamfetamine may increase the antihypertensive activities of Brexpiprazole. Approved, Investigational Brimonidine Lisdexamfetamine may decrease the vasoconstricting activities of Brimonidine. Approved Brofaromine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Brofaromine. Experimental Bromocriptine Lisdexamfetamine may decrease the vasoconstricting activities of Bromocriptine. Approved, Investigational Bromodiphenhydramine Lisdexamfetamine may decrease the sedative activities of Bromodiphenhydramine. Approved Bromperidol Bromperidol may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational Brompheniramine Lisdexamfetamine may decrease the sedative activities of Brompheniramine. Approved Bucindolol Bucindolol may increase the antihypertensive activities of Lisdexamfetamine. Investigational Buclizine Lisdexamfetamine may decrease the sedative activities of Buclizine. Approved Bufuralol Bufuralol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Experimental, Investigational Bunazosin Bunazosin may increase the antihypertensive activities of Lisdexamfetamine. Investigational Bupranolol Bupranolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved Buprenorphine Lisdexamfetamine may increase the analgesic activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Butaperazine Butaperazine may decrease the stimulatory activities of Lisdexamfetamine. Experimental Butorphanol Lisdexamfetamine may increase the analgesic activities of Butorphanol. Approved, Illicit, Vet Approved Butriptyline Butriptyline may increase the stimulatory activities of Lisdexamfetamine. Approved Butyric Acid Lisdexamfetamine may decrease the sedative activities of Butyric Acid. Experimental, Investigational Calcium Carbonate Calcium Carbonate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Approved, Investigational Calcium silicate Calcium silicate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Experimental Carbinoxamine Lisdexamfetamine may decrease the sedative activities of Carbinoxamine. Approved Carboxyamidotriazole The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Carboxyamidotriazole. Investigational Carfentanil Lisdexamfetamine may increase the analgesic activities of Carfentanil. Illicit, Investigational, Vet Approved Cariprazine Cariprazine may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational Caroverine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Caroverine. Experimental Caroxazone The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Caroxazone. Withdrawn Carteolol Carteolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved Carvedilol Carvedilol may increase the antihypertensive activities of Lisdexamfetamine. Approved, Investigational Celiprolol Celiprolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved, Investigational Cetirizine Lisdexamfetamine may decrease the sedative activities of Cetirizine. Approved Chlorcyclizine Lisdexamfetamine may decrease the sedative activities of Chlorcyclizine. Approved Chloropyramine Lisdexamfetamine may decrease the sedative activities of Chloropyramine. Approved Chlorphenamine Lisdexamfetamine may decrease the sedative activities of Chlorphenamine. Approved Chlorphenoxamine Lisdexamfetamine may decrease the sedative activities of Chlorphenoxamine. Withdrawn Chlorproethazine Chlorproethazine may decrease the stimulatory activities of Lisdexamfetamine. Experimental Chlorpromazine Chlorpromazine may increase the antihypertensive activities of Lisdexamfetamine. Approved, Investigational, Vet Approved Chlorprothixene Chlorprothixene may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational, Withdrawn Cilnidipine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Cilnidipine. Approved, Investigational Cimetidine Lisdexamfetamine may decrease the sedative activities of Cimetidine. Approved, Investigational Cinnarizine Lisdexamfetamine may decrease the sedative activities of Cinnarizine. Approved, Investigational Cirazoline Lisdexamfetamine may decrease the vasoconstricting activities of Cirazoline. Experimental Clemastine Lisdexamfetamine may decrease the sedative activities of Clemastine. Approved, Investigational Clenbuterol Lisdexamfetamine may decrease the vasoconstricting activities of Clenbuterol. Approved, Investigational, Vet Approved Clevidipine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Clevidipine. Approved, Investigational Clofedanol Lisdexamfetamine may decrease the sedative activities of Clofedanol. Approved, Withdrawn Clomipramine Clomipramine may increase the stimulatory activities of Lisdexamfetamine. Approved, Investigational, Vet Approved Clonidine Lisdexamfetamine may decrease the vasoconstricting activities of Clonidine. Approved Clopenthixol Clopenthixol may decrease the stimulatory activities of Lisdexamfetamine. Experimental Cloranolol Cloranolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Experimental Clothiapine Clothiapine may decrease the stimulatory activities of Lisdexamfetamine. Experimental Clozapine Clozapine may increase the antihypertensive activities of Lisdexamfetamine. Approved Codeine Lisdexamfetamine may increase the analgesic activities of Codeine. Approved, Illicit Cyamemazine Cyamemazine may decrease the stimulatory activities of Lisdexamfetamine. Approved Cyclandelate The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Cyclandelate. Approved Cyclizine Lisdexamfetamine may decrease the sedative activities of Cyclizine. Approved Cyproheptadine Lisdexamfetamine may decrease the sedative activities of Cyproheptadine. Approved Dapiprazole Dapiprazole may increase the antihypertensive activities of Lisdexamfetamine. Approved Dapoxetine Dapoxetine may increase the orthostatic hypotensive activities of Lisdexamfetamine. Investigational Darodipine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Darodipine. Experimental Desipramine Desipramine may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved, Investigational Desloratadine Lisdexamfetamine may decrease the sedative activities of Desloratadine. Approved, Investigational Detomidine Lisdexamfetamine may decrease the vasoconstricting activities of Detomidine. Vet Approved Dexbrompheniramine Lisdexamfetamine may decrease the sedative activities of Dexbrompheniramine. Approved Dexchlorpheniramine Lisdexamfetamine may decrease the sedative activities of Dexchlorpheniramine. Experimental, Investigational Dexchlorpheniramine maleate Lisdexamfetamine may decrease the sedative activities of Dexchlorpheniramine maleate. Approved Dexmedetomidine Lisdexamfetamine may decrease the vasoconstricting activities of Dexmedetomidine. Approved, Vet Approved Dextroamphetamine Dextroamphetamine may increase the antihypertensive activities of Lisdexamfetamine. Approved, Illicit Dextromoramide Lisdexamfetamine may increase the analgesic activities of Dextromoramide. Experimental, Illicit Dextropropoxyphene Lisdexamfetamine may increase the analgesic activities of Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Dezocine Lisdexamfetamine may increase the analgesic activities of Dezocine. Approved, Investigational Dibenzepin Dibenzepin may increase the stimulatory activities of Lisdexamfetamine. Experimental Diclofenamide Diclofenamide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Approved, Investigational Dihydrocodeine Lisdexamfetamine may increase the analgesic activities of Dihydrocodeine. Approved, Illicit Dihydroergotamine Lisdexamfetamine may decrease the vasoconstricting activities of Dihydroergotamine. Approved, Investigational Dihydroetorphine Lisdexamfetamine may increase the analgesic activities of Dihydroetorphine. Experimental, Illicit Dihydromorphine Lisdexamfetamine may increase the analgesic activities of Dihydromorphine. Experimental, Illicit Diltiazem The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Diltiazem. Approved, Investigational Dimenhydrinate Lisdexamfetamine may decrease the sedative activities of Dimenhydrinate. Approved Dimetacrine Dimetacrine may increase the stimulatory activities of Lisdexamfetamine. Approved, Withdrawn Dimetindene Lisdexamfetamine may decrease the sedative activities of Dimetindene. Approved, Investigational Dimetotiazine Lisdexamfetamine may decrease the sedative activities of Dimetotiazine. Approved Diphenhydramine Lisdexamfetamine may decrease the sedative activities of Diphenhydramine. Approved, Investigational Diphenoxylate Lisdexamfetamine may increase the analgesic activities of Diphenoxylate. Approved, Illicit Diphenylpyraline Lisdexamfetamine may decrease the sedative activities of Diphenylpyraline. Approved, Investigational Dipivefrin Lisdexamfetamine may decrease the vasoconstricting activities of Dipivefrin. Approved Dipyridamole Dipyridamole may increase the hypotensive activities of Lisdexamfetamine. Approved Dixyrazine Dixyrazine may decrease the stimulatory activities of Lisdexamfetamine. Experimental DL-Methylephedrine Lisdexamfetamine may decrease the vasoconstricting activities of DL-Methylephedrine. Approved Dobutamine Lisdexamfetamine may decrease the vasoconstricting activities of Dobutamine. Approved Dopexamine Lisdexamfetamine may decrease the vasoconstricting activities of Dopexamine. Approved, Investigational Dosulepin Dosulepin may increase the stimulatory activities of Lisdexamfetamine. Approved Dotarizine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Dotarizine. Investigational Doxazosin Doxazosin may increase the antihypertensive activities of Lisdexamfetamine. Approved Doxepin Doxepin may increase the antihypertensive activities of Lisdexamfetamine. Approved, Investigational Doxofylline Lisdexamfetamine may decrease the vasoconstricting activities of Doxofylline. Approved, Investigational Doxylamine Lisdexamfetamine may decrease the sedative activities of Doxylamine. Approved, Vet Approved DPDPE Lisdexamfetamine may increase the analgesic activities of DPDPE. Experimental Dronedarone Dronedarone may increase the antihypertensive activities of Lisdexamfetamine. Approved Droperidol Droperidol may increase the antihypertensive activities of Lisdexamfetamine. Approved, Vet Approved Droxidopa Lisdexamfetamine may decrease the vasoconstricting activities of Droxidopa. Approved, Investigational Ebastine Lisdexamfetamine may decrease the sedative activities of Ebastine. Approved, Investigational Ecopipam Ecopipam may decrease the stimulatory activities of Lisdexamfetamine. Investigational Efonidipine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Efonidipine. Approved, Investigational Emedastine Lisdexamfetamine may decrease the sedative activities of Emedastine. Approved Epanolol Epanolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Experimental Eperisone The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Eperisone. Approved, Investigational Ephedra Lisdexamfetamine may decrease the vasoconstricting activities of Ephedra. Approved, Nutraceutical, Withdrawn Ephedrine Lisdexamfetamine may decrease the vasoconstricting activities of Ephedrine. Approved Epinastine Lisdexamfetamine may decrease the sedative activities of Epinastine. Approved, Investigational Epinephrine Lisdexamfetamine may increase the antihypertensive activities of Epinephrine. Approved, Vet Approved Ergonovine Lisdexamfetamine may decrease the vasoconstricting activities of Ergonovine. Approved Ergotamine Lisdexamfetamine may decrease the vasoconstricting activities of Ergotamine. Approved Esatenolol Esatenolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Experimental Escitalopram Escitalopram may increase the antihypertensive activities of Lisdexamfetamine. Approved, Investigational Esmirtazapine Lisdexamfetamine may decrease the sedative activities of Esmirtazapine. Investigational Esmolol Esmolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved Etafedrine Lisdexamfetamine may decrease the vasoconstricting activities of Etafedrine. Approved Ethopropazine Lisdexamfetamine may decrease the sedative activities of Ethopropazine. Approved Ethosuximide Lisdexamfetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Ethoxzolamide Ethoxzolamide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Withdrawn Ethylmorphine Lisdexamfetamine may increase the analgesic activities of Ethylmorphine. Approved, Illicit Etilefrine Lisdexamfetamine may decrease the vasoconstricting activities of Etilefrine. Withdrawn Etomidate Lisdexamfetamine may decrease the vasoconstricting activities of Etomidate. Approved Etoperidone Lisdexamfetamine may decrease the sedative activities of Etoperidone. Withdrawn Etorphine Lisdexamfetamine may increase the analgesic activities of Etorphine. Illicit, Vet Approved Famotidine Lisdexamfetamine may decrease the sedative activities of Famotidine. Approved Felodipine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Felodipine. Approved, Investigational Fencamfamine Fencamfamine may decrease the stimulatory activities of Lisdexamfetamine. Approved, Illicit, Withdrawn Fendiline The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Fendiline. Withdrawn Fenoterol Lisdexamfetamine may decrease the vasoconstricting activities of Fenoterol. Approved, Investigational Fentanyl Lisdexamfetamine may increase the analgesic activities of Fentanyl. Approved, Illicit, Investigational, Vet Approved Fexofenadine Lisdexamfetamine may decrease the sedative activities of Fexofenadine. Approved, Investigational Fish oil The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Fish oil. Approved, Nutraceutical Fluanisone Fluanisone may decrease the stimulatory activities of Lisdexamfetamine. Experimental Flunarizine Lisdexamfetamine may decrease the sedative activities of Flunarizine. Approved Flupentixol Flupentixol may increase the antihypertensive activities of Lisdexamfetamine. Approved, Investigational, Withdrawn Fluphenazine Fluphenazine may decrease the stimulatory activities of Lisdexamfetamine. Approved Fluspirilene Fluspirilene may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational Formoterol Lisdexamfetamine may decrease the vasoconstricting activities of Formoterol. Approved, Investigational Fostamatinib Fostamatinib may increase the hypotensive activities of Lisdexamfetamine. Approved, Investigational Furazolidone Furazolidone may increase the hypertensive activities of Lisdexamfetamine. Approved, Investigational, Vet Approved Gabapentin The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Gabapentin. Approved, Investigational Gallopamil The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Gallopamil. Investigational Glutamic Acid The serum concentration of Lisdexamfetamine can be decreased when it is combined with Glutamic Acid. Approved, Nutraceutical Guanabenz Lisdexamfetamine may decrease the vasoconstricting activities of Guanabenz. Approved, Investigational Guanethidine The serum concentration of Lisdexamfetamine can be decreased when it is combined with Guanethidine. Approved Guanfacine Lisdexamfetamine may decrease the vasoconstricting activities of Guanfacine. Approved, Investigational Haloperidol Haloperidol may decrease the stimulatory activities of Lisdexamfetamine. Approved Harmaline The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Harmaline. Experimental Heroin Lisdexamfetamine may increase the analgesic activities of Heroin. Approved, Illicit, Investigational Hexoprenaline Lisdexamfetamine may decrease the vasoconstricting activities of Hexoprenaline. Approved, Withdrawn Higenamine Lisdexamfetamine may decrease the vasoconstricting activities of Higenamine. Investigational Hydracarbazine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Hydracarbazine. Experimental Hydrocodone Lisdexamfetamine may increase the analgesic activities of Hydrocodone. Approved, Illicit Hydromorphone Lisdexamfetamine may increase the analgesic activities of Hydromorphone. Approved, Illicit Hydrotalcite Hydrotalcite may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Approved, Experimental, Investigational Hydroxyzine Lisdexamfetamine may decrease the sedative activities of Hydroxyzine. Approved Iloperidone Iloperidone may increase the antihypertensive activities of Lisdexamfetamine. Approved Imipramine Imipramine may increase the antihypertensive activities of Lisdexamfetamine. Approved Indacaterol Lisdexamfetamine may decrease the vasoconstricting activities of Indacaterol. Approved Indenolol Indenolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Withdrawn Indoramin Indoramin may increase the antihypertensive activities of Lisdexamfetamine. Withdrawn Ioflupane I-123 Lisdexamfetamine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent. Approved Iprindole Iprindole may increase the stimulatory activities of Lisdexamfetamine. Experimental Iproclozide The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Iproclozide. Withdrawn Iproniazid Iproniazid may increase the hypertensive activities of Lisdexamfetamine. Withdrawn Isocarboxazid Isocarboxazid may increase the hypertensive activities of Lisdexamfetamine. Approved Isoetarine Lisdexamfetamine may decrease the vasoconstricting activities of Isoetarine. Approved Isometheptene Lisdexamfetamine may decrease the vasoconstricting activities of Isometheptene. Approved Isoprenaline Lisdexamfetamine may decrease the vasoconstricting activities of Isoprenaline. Approved, Investigational Isothipendyl Lisdexamfetamine may decrease the sedative activities of Isothipendyl. Approved Isoxsuprine Lisdexamfetamine may decrease the vasoconstricting activities of Isoxsuprine. Approved, Withdrawn Isradipine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Isradipine. Approved, Investigational Ketobemidone Lisdexamfetamine may increase the analgesic activities of Ketobemidone. Approved, Investigational Ketotifen Lisdexamfetamine may decrease the sedative activities of Ketotifen. Approved Labetalol Labetalol may increase the antihypertensive activities of Lisdexamfetamine. Approved Lacidipine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Lacidipine. Approved, Investigational Lafutidine Lisdexamfetamine may decrease the sedative activities of Lafutidine. Investigational Lamotrigine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Lamotrigine. Approved, Investigational Landiolol Landiolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Investigational Lavoltidine Lisdexamfetamine may decrease the sedative activities of Lavoltidine. Investigational Lercanidipine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Lercanidipine. Approved, Investigational Levetiracetam The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Levetiracetam. Approved, Investigational Levobetaxolol Levobetaxolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved, Investigational Levocabastine Lisdexamfetamine may decrease the sedative activities of Levocabastine. Approved, Investigational Levocetirizine Lisdexamfetamine may decrease the sedative activities of Levocetirizine. Approved Levomethadyl Acetate Lisdexamfetamine may increase the analgesic activities of Levomethadyl Acetate. Approved, Investigational Levorphanol Lisdexamfetamine may increase the analgesic activities of Levorphanol. Approved Levosalbutamol Lisdexamfetamine may decrease the vasoconstricting activities of Levosalbutamol. Approved, Investigational Lidoflazine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Lidoflazine. Experimental Lithium cation Lithium may decrease the stimulatory activities of Lisdexamfetamine. Experimental Lodoxamide Lisdexamfetamine may decrease the sedative activities of Lodoxamide. Approved Lofentanil Lisdexamfetamine may increase the analgesic activities of Lofentanil. Illicit Lofepramine Lofepramine may increase the stimulatory activities of Lisdexamfetamine. Experimental Lofexidine Lisdexamfetamine may decrease the vasoconstricting activities of Lofexidine. Approved, Investigational Loperamide The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Loperamide. Approved Loratadine Lisdexamfetamine may decrease the sedative activities of Loratadine. Approved, Investigational Lorpiprazole Lisdexamfetamine may decrease the sedative activities of Lorpiprazole. Approved Loxapine Loxapine may decrease the stimulatory activities of Lisdexamfetamine. Approved Lurasidone Lurasidone may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational Magaldrate Magaldrate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Approved, Withdrawn Magnesium carbonate Magnesium carbonate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Approved, Investigational Magnesium hydroxide Magnesium hydroxide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Approved, Investigational Magnesium oxide Magnesium oxide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Approved Magnesium peroxide Magnesium peroxide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Experimental Magnesium silicate Magnesium silicate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Approved Magnesium sulfate The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Magnesium sulfate. Approved, Investigational, Vet Approved Magnesium Trisilicate Magnesium Trisilicate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Approved Manidipine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Manidipine. Approved, Investigational Maprotiline Lisdexamfetamine may decrease the sedative activities of Maprotiline. Approved, Investigational Mebanazine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Mebanazine. Withdrawn Meclizine Lisdexamfetamine may decrease the sedative activities of Meclizine. Approved Medetomidine Lisdexamfetamine may decrease the vasoconstricting activities of Medetomidine. Vet Approved Melitracen Melitracen may increase the stimulatory activities of Lisdexamfetamine. Experimental, Investigational Melperone Melperone may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational Menthol The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Menthol. Approved Mephentermine Lisdexamfetamine may decrease the vasoconstricting activities of Mephentermine. Approved Mepindolol Mepindolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Experimental Meptazinol Lisdexamfetamine may increase the analgesic activities of Meptazinol. Experimental Mepyramine Lisdexamfetamine may decrease the sedative activities of Mepyramine. Approved, Vet Approved Mequitazine Lisdexamfetamine may decrease the sedative activities of Mequitazine. Approved Mesoridazine Mesoridazine may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational Metaraminol Lisdexamfetamine may decrease the vasoconstricting activities of Metaraminol. Approved, Investigational Methadone Lisdexamfetamine may increase the analgesic activities of Methadone. Approved Methadyl Acetate Lisdexamfetamine may increase the analgesic activities of Methadyl Acetate. Approved, Illicit Methamphetamine Lisdexamfetamine may decrease the vasoconstricting activities of Methamphetamine. Approved, Illicit Methantheline Lisdexamfetamine may decrease the sedative activities of Methantheline. Approved, Investigational Methapyrilene Lisdexamfetamine may decrease the sedative activities of Methapyrilene. Withdrawn Methazolamide Methazolamide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Approved Methdilazine Lisdexamfetamine may decrease the sedative activities of Methdilazine. Approved Methenamine The serum concentration of Lisdexamfetamine can be decreased when it is combined with Methenamine. Approved, Vet Approved Methotrimeprazine Methotrimeprazine may increase the antihypertensive activities of Lisdexamfetamine. Approved, Investigational Methoxamine Lisdexamfetamine may decrease the vasoconstricting activities of Methoxamine. Approved, Investigational Methoxyphenamine Lisdexamfetamine may decrease the vasoconstricting activities of Methoxyphenamine. Experimental Methsuximide The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Methsuximide. Approved Methyldopa Lisdexamfetamine may decrease the vasoconstricting activities of Methyldopa. Approved Methylene blue The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Methylene blue. Approved, Investigational Metiamide Lisdexamfetamine may decrease the sedative activities of Metiamide. Experimental Metoprolol Metoprolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved, Investigational Mianserin Lisdexamfetamine may decrease the sedative activities of Mianserin. Approved, Investigational Mibefradil The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Mibefradil. Investigational, Withdrawn Midodrine Lisdexamfetamine may decrease the vasoconstricting activities of Midodrine. Approved Minaprine Minaprine may increase the hypertensive activities of Lisdexamfetamine. Approved Mirabegron Lisdexamfetamine may decrease the vasoconstricting activities of Mirabegron. Approved Mirodenafil Mirodenafil may increase the hypotensive activities of Lisdexamfetamine. Investigational Mirtazapine Lisdexamfetamine may decrease the sedative activities of Mirtazapine. Approved Mizolastine Lisdexamfetamine may decrease the sedative activities of Mizolastine. Investigational Moclobemide Moclobemide may increase the hypertensive activities of Lisdexamfetamine. Approved, Investigational Molindone Molindone may decrease the stimulatory activities of Lisdexamfetamine. Approved Moperone Moperone may decrease the stimulatory activities of Lisdexamfetamine. Experimental Morphine Lisdexamfetamine may increase the analgesic activities of Morphine. Approved, Investigational Mosapramine Mosapramine may decrease the stimulatory activities of Lisdexamfetamine. Experimental Moxonidine Lisdexamfetamine may decrease the vasoconstricting activities of Moxonidine. Approved, Investigational Nadolol Nadolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved Naftopidil The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Naftopidil. Investigational Nalbuphine Lisdexamfetamine may increase the analgesic activities of Nalbuphine. Approved Naphazoline Lisdexamfetamine may decrease the vasoconstricting activities of Naphazoline. Approved Nebivolol Nebivolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved, Investigational Nefazodone Nefazodone may increase the antihypertensive activities of Lisdexamfetamine. Approved, Withdrawn Nialamide Nialamide may increase the hypertensive activities of Lisdexamfetamine. Withdrawn Nicardipine Nicardipine may increase the antihypertensive activities of Lisdexamfetamine. Approved, Investigational Nicergoline Nicergoline may increase the antihypertensive activities of Lisdexamfetamine. Approved, Investigational Nicomorphine Lisdexamfetamine may increase the analgesic activities of Nicomorphine. Experimental Nifedipine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Nifedipine. Approved Niguldipine Niguldipine may increase the antihypertensive activities of Lisdexamfetamine. Experimental Niludipine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Niludipine. Experimental Nilvadipine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Nilvadipine. Approved, Investigational Nimesulide The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Nimesulide. Approved, Investigational, Withdrawn Nimodipine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Nimodipine. Approved, Investigational Nisoldipine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Nisoldipine. Approved Nitrendipine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Nitrendipine. Approved, Investigational Nizatidine Lisdexamfetamine may decrease the sedative activities of Nizatidine. Approved Norepinephrine Lisdexamfetamine may decrease the vasoconstricting activities of Norepinephrine. Approved Norfenefrine Lisdexamfetamine may decrease the vasoconstricting activities of Norfenefrine. Experimental Normethadone Lisdexamfetamine may increase the analgesic activities of Normethadone. Approved, Illicit Nortriptyline Nortriptyline may increase the antihypertensive activities of Lisdexamfetamine. Approved Nylidrin Lisdexamfetamine may decrease the vasoconstricting activities of Nylidrin. Approved Octamoxin The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Octamoxin. Withdrawn Octopamine Lisdexamfetamine may decrease the vasoconstricting activities of Octopamine. Experimental Olanzapine Olanzapine may increase the antihypertensive activities of Lisdexamfetamine. Approved, Investigational Olodaterol Lisdexamfetamine may decrease the vasoconstricting activities of Olodaterol. Approved Olopatadine Lisdexamfetamine may decrease the sedative activities of Olopatadine. Approved Ondansetron Ondansetron may decrease the stimulatory activities of Lisdexamfetamine. Approved Opipramol Opipramol may increase the stimulatory activities of Lisdexamfetamine. Investigational Opium Lisdexamfetamine may increase the analgesic activities of Opium. Approved, Illicit Orciprenaline Lisdexamfetamine may decrease the vasoconstricting activities of Orciprenaline. Approved Orphenadrine Lisdexamfetamine may decrease the sedative activities of Orphenadrine. Approved Osanetant Osanetant may decrease the stimulatory activities of Lisdexamfetamine. Investigational Otilonium The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Otilonium. Experimental, Investigational Oxatomide Lisdexamfetamine may decrease the sedative activities of Oxatomide. Investigational Oxprenolol Oxprenolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved Oxycodone Lisdexamfetamine may increase the analgesic activities of Oxycodone. Approved, Illicit, Investigational Oxyfedrine Lisdexamfetamine may decrease the vasoconstricting activities of Oxyfedrine. Experimental Oxymetazoline Lisdexamfetamine may decrease the vasoconstricting activities of Oxymetazoline. Approved, Investigational Oxymorphone Lisdexamfetamine may increase the analgesic activities of Oxymorphone. Approved, Investigational, Vet Approved Oxypertine Oxypertine may decrease the stimulatory activities of Lisdexamfetamine. Experimental Ozagrel Lisdexamfetamine may decrease the sedative activities of Ozagrel. Investigational Paliperidone Paliperidone may increase the antihypertensive activities of Lisdexamfetamine. Approved Pargyline Pargyline may increase the hypertensive activities of Lisdexamfetamine. Approved Pemirolast Lisdexamfetamine may decrease the sedative activities of Pemirolast. Approved, Investigational Penbutolol Penbutolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved, Investigational Penfluridol Penfluridol may decrease the stimulatory activities of Lisdexamfetamine. Experimental Pentazocine Lisdexamfetamine may increase the analgesic activities of Pentazocine. Approved, Vet Approved Pentoxifylline Pentoxifylline may increase the hypotensive activities of Lisdexamfetamine. Approved, Investigational Perazine Perazine may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational Pergolide Lisdexamfetamine may decrease the vasoconstricting activities of Pergolide. Approved, Investigational, Vet Approved, Withdrawn Perospirone Perospirone may decrease the stimulatory activities of Lisdexamfetamine. Approved Perphenazine Perphenazine may decrease the stimulatory activities of Lisdexamfetamine. Approved Pethidine Lisdexamfetamine may increase the analgesic activities of Pethidine. Approved Phenazocine Lisdexamfetamine may increase the analgesic activities of Phenazocine. Experimental Phendimetrazine Lisdexamfetamine may decrease the vasoconstricting activities of Phendimetrazine. Approved, Illicit Phenelzine Phenelzine may increase the hypertensive activities of Lisdexamfetamine. Approved Phenindamine Lisdexamfetamine may decrease the sedative activities of Phenindamine. Approved Pheniprazine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Pheniprazine. Withdrawn Pheniramine Lisdexamfetamine may decrease the sedative activities of Pheniramine. Approved Phenobarbital The serum concentration of Phenobarbital can be decreased when it is combined with Lisdexamfetamine. Approved, Investigational Phenoperidine Lisdexamfetamine may increase the analgesic activities of Phenoperidine. Experimental Phenoxybenzamine Phenoxybenzamine may increase the antihypertensive activities of Lisdexamfetamine. Approved Phenoxypropazine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Phenoxypropazine. Withdrawn Phentolamine Phentolamine may increase the antihypertensive activities of Lisdexamfetamine. Approved Phenylephrine Lisdexamfetamine may decrease the vasoconstricting activities of Phenylephrine. Approved Phenylpropanolamine Lisdexamfetamine may decrease the vasoconstricting activities of Phenylpropanolamine. Approved, Vet Approved, Withdrawn Phenytoin The serum concentration of Phenytoin can be decreased when it is combined with Lisdexamfetamine. Approved, Vet Approved Pimozide Pimozide may decrease the stimulatory activities of Lisdexamfetamine. Approved Pinaverium The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Pinaverium. Approved Pindolol Pindolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved, Investigational Pipamperone Pipamperone may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational Pipotiazine Pipotiazine may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational Pirbuterol Lisdexamfetamine may decrease the vasoconstricting activities of Pirbuterol. Approved Piritramide Lisdexamfetamine may increase the analgesic activities of Piritramide. Approved, Investigational Pirlindole Pirlindole may increase the hypertensive activities of Lisdexamfetamine. Approved Pitolisant Lisdexamfetamine may decrease the sedative activities of Pitolisant. Approved, Investigational Pivhydrazine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Pivhydrazine. Withdrawn Pizotifen Pizotifen may increase the antihypertensive activities of Lisdexamfetamine. Approved Platelet Activating Factor Platelet Activating Factor may increase the orthostatic hypotensive activities of Lisdexamfetamine. Experimental Practolol Practolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved Prazosin Prazosin may increase the antihypertensive activities of Lisdexamfetamine. Approved Prenalterol Lisdexamfetamine may decrease the vasoconstricting activities of Prenalterol. Experimental Prenylamine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Prenylamine. Withdrawn Procaine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Procaine. Approved, Investigational, Vet Approved Procarbazine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Procarbazine. Approved, Investigational Procaterol Lisdexamfetamine may decrease the vasoconstricting activities of Procaterol. Approved, Investigational Prochlorperazine Prochlorperazine may decrease the stimulatory activities of Lisdexamfetamine. Approved, Vet Approved Promazine Promazine may increase the antihypertensive activities of Lisdexamfetamine. Approved, Vet Approved Promethazine Lisdexamfetamine may decrease the sedative activities of Promethazine. Approved, Investigational Propafenone Propafenone may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved Propericiazine Propericiazine may increase the antihypertensive activities of Lisdexamfetamine. Approved, Investigational Propiomazine Propiomazine may increase the antihypertensive activities of Lisdexamfetamine. Approved Propiverine Propiverine may increase the antihypertensive activities of Lisdexamfetamine. Approved, Investigational Propranolol Propranolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved, Investigational Prothipendyl Prothipendyl may decrease the stimulatory activities of Lisdexamfetamine. Investigational Protokylol Lisdexamfetamine may decrease the vasoconstricting activities of Protokylol. Approved, Vet Approved Protriptyline Protriptyline may increase the stimulatory activities of Lisdexamfetamine. Approved Pseudoephedrine Lisdexamfetamine may decrease the vasoconstricting activities of Pseudoephedrine. Approved Quetiapine Quetiapine may increase the antihypertensive activities of Lisdexamfetamine. Approved Quifenadine Lisdexamfetamine may decrease the sedative activities of Quifenadine. Experimental Quinidine Quinidine may increase the antihypertensive activities of Lisdexamfetamine. Approved, Investigational Racepinephrine Lisdexamfetamine may increase the antihypertensive activities of Racepinephrine. Approved Raclopride Raclopride may decrease the stimulatory activities of Lisdexamfetamine. Investigational Ractopamine Lisdexamfetamine may decrease the vasoconstricting activities of Ractopamine. Vet Approved Ranitidine Lisdexamfetamine may decrease the sedative activities of Ranitidine. Approved Rasagiline Rasagiline may increase the hypertensive activities of Lisdexamfetamine. Approved Remifentanil Lisdexamfetamine may increase the analgesic activities of Remifentanil. Approved Remoxipride Remoxipride may decrease the stimulatory activities of Lisdexamfetamine. Approved, Withdrawn Reproterol Lisdexamfetamine may decrease the vasoconstricting activities of Reproterol. Investigational Reserpine Reserpine may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational Rilmenidine Lisdexamfetamine may decrease the vasoconstricting activities of Rilmenidine. Approved, Investigational Rimiterol Lisdexamfetamine may decrease the vasoconstricting activities of Rimiterol. Experimental Risperidone Risperidone may increase the antihypertensive activities of Lisdexamfetamine. Approved, Investigational Ritanserin Ritanserin may decrease the stimulatory activities of Lisdexamfetamine. Investigational Ritobegron Lisdexamfetamine may decrease the vasoconstricting activities of Ritobegron. Investigational Ritodrine Lisdexamfetamine may decrease the vasoconstricting activities of Ritodrine. Approved, Investigational Romifidine Lisdexamfetamine may decrease the vasoconstricting activities of Romifidine. Vet Approved Ropinirole Lisdexamfetamine may decrease the vasoconstricting activities of Ropinirole. Approved, Investigational Roxatidine acetate Lisdexamfetamine may decrease the sedative activities of Roxatidine acetate. Approved, Investigational Rupatadine Lisdexamfetamine may decrease the sedative activities of Rupatadine. Approved Safrazine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Safrazine. Withdrawn Salbutamol Lisdexamfetamine may decrease the vasoconstricting activities of Salbutamol. Approved, Vet Approved Salmeterol Lisdexamfetamine may decrease the vasoconstricting activities of Salmeterol. Approved Selegiline The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Selegiline. Approved, Investigational, Vet Approved Seletracetam The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Seletracetam. Investigational Sertindole Sertindole may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational, Withdrawn Sildenafil Sildenafil may increase the hypotensive activities of Lisdexamfetamine. Approved, Investigational Silodosin Silodosin may increase the antihypertensive activities of Lisdexamfetamine. Approved Sodium bicarbonate Sodium bicarbonate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Approved Solabegron Lisdexamfetamine may decrease the vasoconstricting activities of Solabegron. Investigational Sotalol Sotalol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved Sufentanil Lisdexamfetamine may increase the analgesic activities of Sufentanil. Approved, Investigational Sulpiride Sulpiride may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational Sultopride Sultopride may decrease the stimulatory activities of Lisdexamfetamine. Experimental Synephrine Lisdexamfetamine may decrease the vasoconstricting activities of Synephrine. Experimental Tadalafil Tadalafil may increase the hypotensive activities of Lisdexamfetamine. Approved, Investigational Talinolol Talinolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Investigational Tamsulosin Tamsulosin may increase the antihypertensive activities of Lisdexamfetamine. Approved, Investigational Tapentadol Lisdexamfetamine may increase the analgesic activities of Tapentadol. Approved Terazosin Terazosin may increase the antihypertensive activities of Lisdexamfetamine. Approved Terbutaline Terbutaline may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved Terfenadine Lisdexamfetamine may decrease the sedative activities of Terfenadine. Approved, Withdrawn Terodiline The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Terodiline. Experimental Tertatolol Tertatolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Experimental Tesmilifene Lisdexamfetamine may decrease the sedative activities of Tesmilifene. Investigational Tetrahydropalmatine Tetrahydropalmatine may decrease the stimulatory activities of Lisdexamfetamine. Investigational Tetryzoline Lisdexamfetamine may decrease the vasoconstricting activities of Tetryzoline. Approved Theophylline Theophylline may increase the hypotensive activities of Lisdexamfetamine. Approved Thiopropazate Thiopropazate may decrease the stimulatory activities of Lisdexamfetamine. Experimental Thioproperazine Thioproperazine may increase the antihypertensive activities of Lisdexamfetamine. Approved Thioridazine Thioridazine may increase the antihypertensive activities of Lisdexamfetamine. Approved, Withdrawn Thiothixene Thiothixene may decrease the stimulatory activities of Lisdexamfetamine. Approved Thonzylamine Lisdexamfetamine may decrease the sedative activities of Thonzylamine. Approved Tianeptine Tianeptine may increase the stimulatory activities of Lisdexamfetamine. Approved, Investigational Tiapride Tiapride may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational Tilidine Lisdexamfetamine may increase the analgesic activities of Tilidine. Experimental Timolol Timolol may increase the orthostatic hypotensive activities of Lisdexamfetamine. Approved Tizanidine Lisdexamfetamine may decrease the vasoconstricting activities of Tizanidine. Approved, Investigational Tolazoline Tolazoline may increase the antihypertensive activities of Lisdexamfetamine. Approved, Vet Approved Tolfenamic Acid The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Tolfenamic Acid. Approved, Investigational Toloxatone Toloxatone may increase the hypertensive activities of Lisdexamfetamine. Approved Tramadol Lisdexamfetamine may increase the analgesic activities of Tramadol. Approved, Investigational Tranilast Lisdexamfetamine may decrease the sedative activities of Tranilast. Approved, Investigational Tranylcypromine Tranylcypromine may increase the hypertensive activities of Lisdexamfetamine. Approved, Investigational Trazodone Trazodone may increase the antihypertensive activities of Lisdexamfetamine. Approved, Investigational Tretoquinol Lisdexamfetamine may decrease the vasoconstricting activities of Tretoquinol. Experimental Trifluoperazine Trifluoperazine may increase the antihypertensive activities of Lisdexamfetamine. Approved, Investigational Trifluperidol Trifluperidol may decrease the stimulatory activities of Lisdexamfetamine. Experimental Triflupromazine Triflupromazine may decrease the stimulatory activities of Lisdexamfetamine. Approved, Vet Approved Trimazosin Trimazosin may increase the antihypertensive activities of Lisdexamfetamine. Experimental Trimebutine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Trimebutine. Approved Trimethadione The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Trimethadione. Approved Trimipramine Trimipramine may increase the antihypertensive activities of Lisdexamfetamine. Approved Tripelennamine Lisdexamfetamine may decrease the sedative activities of Tripelennamine. Approved, Vet Approved Triprolidine Lisdexamfetamine may decrease the sedative activities of Triprolidine. Approved Tritoqualine Lisdexamfetamine may decrease the sedative activities of Tritoqualine. Approved Tromethamine Tromethamine may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. Approved Tulobuterol Lisdexamfetamine may decrease the vasoconstricting activities of Tulobuterol. Investigational Udenafil Udenafil may increase the hypotensive activities of Lisdexamfetamine. Approved, Investigational Urapidil Urapidil may increase the antihypertensive activities of Lisdexamfetamine. Investigational Vardenafil Vardenafil may increase the hypotensive activities of Lisdexamfetamine. Approved Veralipride Veralipride may decrease the stimulatory activities of Lisdexamfetamine. Experimental Verapamil Verapamil may increase the antihypertensive activities of Lisdexamfetamine. Approved Vilanterol Lisdexamfetamine may decrease the vasoconstricting activities of Vilanterol. Approved Vinpocetine The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Vinpocetine. Investigational WIN 55212-2 The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with WIN 55212-2. Experimental Xamoterol Lisdexamfetamine may decrease the vasoconstricting activities of Xamoterol. Experimental Xylazine Lisdexamfetamine may decrease the vasoconstricting activities of Xylazine. Vet Approved Xylometazoline Lisdexamfetamine may decrease the vasoconstricting activities of Xylometazoline. Approved, Investigational Ziconotide The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Ziconotide. Approved Ziprasidone Ziprasidone may increase the antihypertensive activities of Lisdexamfetamine. Approved Zonisamide The risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Zonisamide. Approved, Investigational Zotepine Zotepine may decrease the stimulatory activities of Lisdexamfetamine. Approved, Investigational, Withdrawn Zuclopenthixol Zuclopenthixol may increase the antihypertensive activities of Lisdexamfetamine. Approved, Investigational - Food Interactions
- Not Available
References
- Synthesis Reference
Michael J. Bauer, Gary Richard Callen, Judi Christine Humphrey, Todd Jeffrey Johnson, Matthew Wendell Schiesher, "Methods and Compositions for Preparing Lisdexamfetamine and Salts Thereof." U.S. Patent US20120157706, issued June 21, 2012.
US20120157706- General References
- Jasinski DR, Krishnan S: Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol. 2009 Jun;23(4):410-8. doi: 10.1177/0269881108093841. Epub 2008 Jul 17. [PubMed:18635707]
- Madaan V: Lisdexamfetamine dimesylate for childhood ADHD. Drugs Today (Barc). 2008 May;44(5):319-24. doi: 10.1358/dot.2008.44.5.1215724. [PubMed:18548134]
- Krishnan S, Moncrief S: An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):180-4. Epub 2006 Oct 11. [PubMed:17035599]
- External Links
- Human Metabolome Database
- HMDB0015385
- PubChem Compound
- 11597698
- PubChem Substance
- 46505358
- ChemSpider
- 9772458
- ChEBI
- 135925
- ChEMBL
- CHEMBL1201222
- Therapeutic Targets Database
- DAP000571
- PharmGKB
- PA164748975
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Lisdexamfetamine
- ATC Codes
- N06BA12 — Lisdexamfetamine
- AHFS Codes
- 28:20.04 — Amphetamines
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- New River Pharmaceuticals Inc.
- Patheon Inc.
- Physicians Total Care Inc.
- Quality Care
- Shire Inc.
- Dosage forms
Form Route Strength Capsule Oral 10 mg/1 Capsule Oral 10 mg Capsule Oral 20 mg/1 Capsule Oral 20 mg Capsule Oral 30 mg Capsule Oral 30 mg/1 Capsule Oral 40 mg Capsule Oral 40 mg/1 Capsule Oral 50 mg Capsule Oral 50 mg/1 Capsule Oral 60 mg Capsule Oral 60 mg/1 Capsule Oral 70 mg/1 Capsule Oral 70 mg Tablet, chewable Oral 10 mg/1 Tablet, chewable Oral 20 mg/1 Tablet, chewable Oral 30 mg/1 Tablet, chewable Oral 40 mg/1 Tablet, chewable Oral 50 mg/1 Tablet, chewable Oral 60 mg/1 - Prices
Unit description Cost Unit Vyvanse 30 mg capsule 6.24USD capsule Vyvanse 50 mg capsule 6.02USD capsule Vyvanse 70 mg capsule 5.85USD capsule Vyvanse 40 mg capsule 5.8USD capsule Vyvanse 20 mg capsule 5.26USD capsule Vyvanse 60 mg capsule 5.02USD capsule DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US7659253 No 2003-02-24 2023-02-24 US US7718619 No 2003-02-24 2023-02-24 US US7659254 No 2003-02-24 2023-02-24 US US7671030 No 2003-02-24 2023-02-24 US US7662788 No 2003-02-24 2023-02-24 US US7687467 No 2003-02-24 2023-02-24 US US7678770 No 2003-02-24 2023-02-24 US US7671031 No 2003-02-24 2023-02-24 US US7713936 No 2003-02-24 2023-02-24 US US7674774 No 2003-02-24 2023-02-24 US US7678771 No 2003-02-24 2023-02-24 US US7655630 No 2003-02-24 2023-02-24 US US7687466 No 2003-02-24 2023-02-24 US US7223735 No 2003-02-24 2023-02-24 US US7700561 No 2003-02-24 2023-02-24 US US7662787 No 2003-02-24 2023-02-24 US US7723305 No 2003-02-24 2023-02-24 US US7105486 No 2003-02-24 2023-02-24 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility 792 mg/mL (dimesylate salt) Not Available logP 1.06 Not Available - Predicted Properties
Property Value Source Water Solubility 0.0877 mg/mL ALOGPS logP 1.01 ALOGPS logP 1.14 ChemAxon logS -3.5 ALOGPS pKa (Strongest Acidic) 15.89 ChemAxon pKa (Strongest Basic) 10.21 ChemAxon Physiological Charge 2 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 81.14 Å2 ChemAxon Rotatable Bond Count 8 ChemAxon Refractivity 78.31 m3·mol-1 ChemAxon Polarizability 31.28 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9858 Blood Brain Barrier + 0.9444 Caco-2 permeable + 0.664 P-glycoprotein substrate Substrate 0.6919 P-glycoprotein inhibitor I Non-inhibitor 0.9264 P-glycoprotein inhibitor II Non-inhibitor 0.9802 Renal organic cation transporter Non-inhibitor 0.8398 CYP450 2C9 substrate Non-substrate 0.8303 CYP450 2D6 substrate Non-substrate 0.621 CYP450 3A4 substrate Non-substrate 0.7228 CYP450 1A2 substrate Non-inhibitor 0.7025 CYP450 2C9 inhibitor Non-inhibitor 0.9337 CYP450 2D6 inhibitor Non-inhibitor 0.858 CYP450 2C19 inhibitor Non-inhibitor 0.7568 CYP450 3A4 inhibitor Non-inhibitor 0.5499 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8494 Ames test Non AMES toxic 0.7156 Carcinogenicity Non-carcinogens 0.854 Biodegradation Not ready biodegradable 0.8575 Rat acute toxicity 2.0058 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9688 hERG inhibition (predictor II) Non-inhibitor 0.9004
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acid amides
- Alternative Parents
- Amphetamines and derivatives / Phenylpropanes / N-acyl amines / Secondary carboxylic acid amides / Organopnictogen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Alpha-amino acid amide / Amphetamine or derivatives / Phenylpropane / Monocyclic benzene moiety / Fatty amide / Fatty acyl / Benzenoid / N-acyl-amine / Carboxamide group / Secondary carboxylic acid amide
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Monoamine transmembrane transporter activity
- Specific Function
- Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
- Gene Name
- SLC6A3
- Uniprot ID
- Q01959
- Uniprot Name
- Sodium-dependent dopamine transporter
- Molecular Weight
- 68494.255 Da
References
- Hamidovic A, Dlugos A, Palmer AA, de Wit H: Polymorphisms in dopamine transporter (SLC6A3) are associated with stimulant effects of D-amphetamine: an exploratory pharmacogenetic study using healthy volunteers. Behav Genet. 2010 Mar;40(2):255-61. doi: 10.1007/s10519-009-9331-7. Epub 2010 Jan 21. [PubMed:20091113]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Protein heterodimerization activity
- Specific Function
- This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
- Gene Name
- ADRA1B
- Uniprot ID
- P35368
- Uniprot Name
- Alpha-1B adrenergic receptor
- Molecular Weight
- 56835.375 Da
References
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Drug created on May 14, 2007 19:24 / Updated on July 16, 2018 21:21